In response to the development progress of the Wuhan pneumonia (new crown pneumonia, COVID-19) vaccine, Liang Gengyi, the head of the research and development team of the Epidemic Command Center, pointed out today (3) that the progress of the development of vaccines and drugs in various units in China is quite smooth, and clinical trials are expected to start before the end of the year. At present, the ability of new drugs to suppress viruses is as high as 90%.

The Central Epidemic Command Center stated today that in this Wuhan pneumonia epidemic, Taiwan has succeeded in preventing the epidemic with the efforts of the government and the people. However, in the face of the international epidemic, the vaccines and drugs used for the prevention and treatment of the new coronavirus will be important tools for subsequent epidemic prevention work.

Regarding the development progress of the Wuhan pneumonia vaccine, the command pointed out that the National Health Institute uses four technology platforms to develop simultaneously and can enter human clinical trials as soon as this fall; the nano vaccine developed by the Academia Sinica is currently undergoing vaccine formulation and dosage. Optimization. The results of these two research units have been negotiated with domestic manufacturers and cooperation has been initiated. In addition, vaccines developed by domestic manufacturers are also expected to enter clinical human trials before the end of this year.

The command center further explained that in terms of new drug development, the domestic academic and research community is also actively developing candidate drugs for the treatment of new coronaviruses. For example, the National Health Institute team has found compounds with inhibitory effects on new coronaviruses. The preliminary experimental results show that they have great potential and value.

The Academia Sinica team screened the main protease inhibitor of the new coronavirus. This potent protease inhibitor can inhibit the replication of the new coronavirus in vitro. The Chang Gung University team, the National Health Institute, and the pre-medical institute team also found monoclonal antibody drugs, which can inhibit the new coronavirus by more than 90%.

Liang Gungyi, head of the R&D team of the Central Epidemic Command Center.

The command center stated that after the national mask team, the national science and technology epidemic prevention team has also taken shape. Combined with the reserves of production, government, education, and research, Taiwan has sufficient self-protection capabilities in response to the recurrence of the epidemic, and can continue to make a difference in global epidemic prevention. contribution.